| HOME >> BIOLOGY >> TECHNOLOGY |
Prior to Corus, Mr. Duncan held positions at Pathogenesis Inc. and Lyondell Chemical.
At Horizon, Mr. Duncan will lead all manufacturing, quality control and
supply chain activities. Mr. Duncan has a bachelor's degree in biology from
The Company recently announced that its lead product HZT-501 met the primary endpoints in two Phase 3 clinical studies, REDUCE-1 and REDUCE-2 (The Registration Endoscopic Study to Determine Ulcer Formation of HZT-501 Compared to Ibuprofen: Efficacy and Safety Study). In REDUCE-1, 24-week treatment with HZT-501 resulted in a statistically significant reduction in gastric ulcers versus treatment with ibuprofen alone. In REDUCE-2, 24-week treatment with HZT-501 resulted in a statistically significant reduction in gastric and/or duodenal ulcers versus treatment with ibuprofen alone.
The trials were conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) and based on the results the Company plans to submit filings to U.S. and European regulatory authorities in 2009.
About Horizon Therapeutics
Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company
focused on the development and commercialization of therapies for the
treatment of mild-to-moderate pain and arthritis. Horizon's clinical
portfolio includes innovative combination therapies in early- and late-stage
development that are designed to improve safety, efficacy and patient
compliance. For more information about the company and its products, please
visit
| SOURCE Horizon Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved |